A retrospective observational study of monotherapy outcomes on the efficacy of third-line or later treatment for patients with HER2 positive unresectable recurrent or metastatic gastric cancer previously treated with trastuzumab
Not Applicable
- Conditions
- HER2 positive unresectable recurrent or metastatic gastric cancer
- Registration Number
- JPRN-UMIN000040853
- Lead Sponsor
- Graduate school of Medicine OSAKA UniversityDepartment of Gastroenterological Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who declined this study before database lock
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival, Real world, Progression-free survival, Duration of response, Time to treatment failure, Objective response rate, Disease control rate
- Secondary Outcome Measures
Name Time Method